Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.
CONCLUSIONS: The T10 patient cohort in 2012 accounted for nearly 40% of overall healthcare expenditures. However, cost differences between the T10 and B90 patients were not attributable to psoriasis-related biologic treatment utilization and costs. The T10 patients had significantly more inpatient and emergency utilization, and comorbid medical conditions.
PMID: 28320213 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Corticosteroid Therapy | Depression | Dermatology | Diabetes | Emergency Medicine | Endocrinology | Healthcare Costs | Heart | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin | Study